2013 Innovation Operations Pharmaceuticals 
Harvard Business Review
MAY 20, 2014
As of 2013, the top ten banks had 70% of the market. In pharmaceuticals, the largest company, Pfizer, is the result of decades of mergers. When a company had dozens of potential competitors in various geographic regions, there was an incentive to innovate before the other guy does.
Harvard Business Review
OCTOBER 24, 2013
Between October 1 and 17, the federal government ceased all nonessential operations because of a partisan stalemate over Obamacare. noted the irony that because of sequester cuts, NIH funding was reduced for the research that resulted in Yale’s James Rothman sharing in the 2013 Nobel Prize for Medicine. Cuts to 2013 budget: $11.08
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
NOVEMBER 30, 2017
A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. Policy can help through measures like capital access programs, business accelerators, or tax incentives.
Harvard Business Review
FEBRUARY 11, 2016
McKesson, the US-based pharmaceutical and health-care giant, benefits from external expertise as a strategic extension of its resources in areas such as business strategy and logistics support. Innovative companies are leading the way, applying a broader palette of talent options and relying on more varied types of relationships.
Harvard Business Review
JUNE 24, 2015
The f ive forces framework for strategy may be valid in one arena, blue ocean or open innovation in another, but each approach to strategy tends to be presented or perceived as a panacea. The firm can innovate to address a tired industry business model or can recognize a megatrend before others see and act on it.
Expert insights. Personalized for you.
11 
Let's personalize your content